Background: Adoption of electronic health record systems has increased the availability of patient-level electronic health information.
T
he widespread adoption of electronic health record systems has markedly increased the availability of patientlevel electronic health information. This information has substantial value across a range of uses, including research (for example, observational comparative effectiveness research), public health (for example, disease surveillance), and health care quality (for example, measuring and monitoring the quality of health services) (1) . It also has substantial commercial value. For example, a pharmaceutical company might be interested in understanding the clinical circumstances when physicians choose one medication over another (2) . Given this value across a range of social and commercial purposes, there has been considerable debate around the role that patient consent should play in the use of electronic health information.
Although digital technology is increasing the availability and usability of patient information, the debate and ethical considerations around the release and reuse of this information are not new. One view is that health information should not be reused without patient consent. Because this information was derived from patients, it should be seen as their own, and as such, patients should retain a right to privacy (3) . This right to privacy is foundational to trust in physicians and medical institutions (4) . Many studies support this view by showing that patients harbor substantial concerns about harm from loss of privacy, including potential discrimination that could come from disclosure of their personal health information (5, 6) . Despite assurances about information security, patients value autonomy so that, even if they intend to share their health information, they still want to be asked (7) (8) (9) (10) .
An alternative view that is substantially more goaldirected, reflecting the irreplaceable social value that individual health information can provide when aggregated across populations (11, 12) , is that obtaining patient consent for using health information would be infeasible (13) and that refusals would create bias and undermine the social value (14) . Whereas the view that patient information should never be reused without consent focuses on the rights of patients, this alternative view places importance on societal benefits that might trump patients' rights. More pointed arguments in favor of reuse suggest that patients may have some obligation to share information for socially beneficial purposes based on conventions of societal participation or more transactional interpretations of who has paid for the health services that often generate these data (15) . Some experts have proposed blanket opt-in or optout consent policies to overcome these concerns. However, even modest rates of nonparticipation can lead to selection bias (14, 16 -18) .
In the wake of this debate, the U.S. Department of Health and Human Services has proposed new regulations that would relax requirements for consent for informationbased research that poses minimal risk to participants (19) . Specifically, the "exempt" category for research would be expanded to include studies in which the risk is largely informational and not physical (19) . The exempt category would be renamed "excused" because these studies would not be subjected to review by an institutional review board but would have to comply with data security standards. This proposal mirrored recommendations from the Institute of Medicine (20, 21) . Both the U.S. Department of Health and Human Services proposal and the Institute of Medicine report argue that we should focus less on consent and more on data security to protect against harm, but the proposals in particular have yet to move forward.
Because consent for health information use has been central to current policies on data use, but both new proposals subordinate the role of consent, we examined public perceptions of the importance of such consent. We performed a national experimental survey, structured as a randomized, controlled experiment, to examine public perceptions of different uses of information (research vs. marketing) and different ways of framing the reporting of that information (an abstract future use vs. a past specific use with reported results) with and without consent.
METHODS

Participants and Survey Administration
We recruited participants from an online research panel assembled by Growth from Knowledge (GfK) Knowledge Networks (22), as previously described (23).
Participants were recruited by GfK Knowledge Networks through a combination of probability-based random-digit dialing and address-based sampling to create a nationally representative panel. This sampling provided coverage of households with and without telephone lines or computer access. The GfK Knowledge Networks provided a computer and Internet access to persons without them in exchange for participation. Participants with computer and Internet access received modest compensation for participation. This method of sampling and panel creation has been shown to yield estimates similar to those derived from random-digit dialing telephone surveys (24) .
We limited our sample to persons in 3 racial/ethnic populations: non-Hispanic African American, non-Hispanic white, and Hispanic (African American and white; English-and Spanish-speaking households). We oversampled African American and Hispanic persons from the panel to allow for sufficiently powered comparisons among the 3 racial/ethnic populations because of concerns of mistrust among minority populations about biomedical research (25) (26) (27) .
We excluded participants who completed the survey in less than half the median completion time. We made this decision before survey administration because we felt these persons were unlikely to have fully read individual survey items before responding. Pretest piloting showed that these persons had little item-to-item variation in their survey responses, which suggested a low level of attention to item content.
We administered the survey electronically on 9 November 2012 through 2 December 2012. The University of Pennsylvania Institutional Review Board approved the study protocol.
Survey Instrument
The survey instrument included measures of health and health care access, a separate conjoint experiment testing the importance of several factors on willingness to share health information in the context of cancer prevention (23) , and vignettes describing secondary uses of electronic health information (Supplement, available at www.annals .org). Participants were told that the survey was about "their views about health information technology and health care in the United States."
Vignettes: Scenarios Describing Uses of Electronic Health Information
We created 8 vignettes describing the use of electronic health information that reflected the rate and predictors of use of a hypothetical pharmacologic treatment of diabetes. The 8 vignettes were identical except, in a 2 ϫ 2 ϫ 2 design, they systematically varied along 3 dimensions ( Figure  1 ): patient consent (obtained vs. not obtained), use (research vs. commercial marketing), and the framing of how the findings would be or were used (an abstract future use without results vs. a past specific use with reported results). For example, the vignette that described a scenario in
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Original Research Consent for Secondary Use of Health Information which consent was not obtained, health information was used for research, and the specific results were reported as follows:
An analysis of thousands of electronic patient records identified people with diabetes. Because it would be very hard to contact all patients, the patients were not asked permission for their records to be reviewed. An ethics review board determined that this study provided acceptable safeguards to patient privacy. University researchers used this information to find out that on average 1 out of 10 patients with diabetes are receiving the drug Diamed for their diabetes. They published their results in a medical journal so that doctors can learn how to improve diabetes care.
Other vignettes reported the goals to be for marketing. In this case, which also describes an abstract future use without results (in contrast to the previous example), the vignette read, "a drug company will use this information to learn more about which types of patients are receiving the company's drug Diamed for their diabetes." For cases in which consent was obtained, the vignette read, "all of the patients will give permission for their records to be reviewed." Because we were interested in how the 3 attributes (consent, use, and framing) influenced attitudes, we included a statement in all vignettes that "an ethics review board determined that this study provided acceptable safeguards to patient privacy" to standardize the level of privacy oversight across the scenarios. The full experimental design of the vignettes is shown in Figure 1 .
We randomly assigned each participant to receive 2 of the possible 8 vignettes. To avoid influencing the response to the second vignette by highly contrasted elements of the first, consent and future or past framing were varied between but not within participants so that each participant received vignettes describing the same consent arrangement (with or without consent) and the same framing of information use (abstract future or specific past) but different uses (research and marketing), resulting in 4 experimental groups. Although we felt different uses would be the least susceptible to order effects, we accounted for potential within-participant order effects in our analytic models. After presenting the participant with the vignette, we asked participants, "How appropriate is this use of patient health information?" on a scale of 1 (not at all appropriate) to 10 (very appropriate). Using this design, we measured the independent effects of consent, use, and framing on support for secondary use of electronic health information.
Health and Access to Care Measures
In prior studies, health status has been inconsistently linked to willingness to share health information for research purposes (5, 28) . We measured self-rated health with a single item from the Behavioral Risk Factor Surveillance System (29). We determined whether a participant 
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An analysis of thousands of electronic patient records identifies persons with diabetes. had a usual source of care, had insurance coverage, and had experienced cost-related barriers to care in the past year using items from the National Health Interview Survey (30).
Demographics
We obtained previously collected demographic information on our study participants from GfK Knowledge Networks, including race, income, educational attainment, sex, age, and whether they lived in a rural or metropolitan area.
Statistical Analysis
We compared demographic characteristics between participants who responded and those who did not respond using chi-square tests, t tests, and analysis of variance. We then compared respondents' ratings for each combination of the 3 information use attributes (consent, use, and framing) between racial/ethnic groups (nonHispanic white, non-Hispanic African American, and Hispanic) using analysis of variance. We used linear regression models to assess the association between the outcome (appropriateness) on a continuous scale, information use attributes, and participant characteristics. We used generalized estimating equations with a working independence correlation structure and robust (Huber-White) variance estimation (31) to account for the correlation of vignettes nested within the respondent induced by the study design. We also adjusted for vignette order in these models because each respondent rated 2 vignettes describing 2 different uses of health information (research and marketing). To account for survey nonresponse and the planned oversampling scheme, we used poststratification weights provided by GfK Knowledge Networks. Few if any data were missing (Ͻ0.5% on all covariates); hence, analyses were conducted on observed data only. We used Wald tests to compare variables. All tests were 2-sided with a type I error rate of 0.05. We conducted all analyses in SAS, version 9.3 (SAS Institute).
Role of the Funding Source
The National Human Genome Research Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
RESULTS
Of 5119 persons from the GfK Knowledge Networks panel invited to participate, 3336 participated for a response rate of 65%. After excluding 272 who finished the survey in less than half the median time, we had a final sample of 3064 participants that included 2093 nonHispanic white, 455 non-Hispanic African American, and 516 Hispanic persons. The characteristics of respondents are presented in Table 1 . Compared with respondents, persons who did not respond were more likely to be younger, have less education, have lower income, and were slightly more likely to be female. We used poststratification weights in our analyses to account for nonresponse bias. The demographic characteristics across the 4 experimental groups were similar except for small differences in the proportion in fair or poor health (range, 13.3% to 18.2%; P ϭ 0.032).
Mean respondent ratings ranged from a low of 3.81 (1 [not at all appropriate]; 10 [very appropriate]) for the scenario describing a marketing use when consent was not Original Research Consent for Secondary Use of Health Information obtained and the framing was specific to a high of 7.06 for the scenario describing a research use when consent was obtained and the framing was specific. The unadjusted means for the 8 scenarios are presented in Table 2 . For marketing uses, there were differences by race/ethnicity (less support among non-Hispanic white persons) but no differences in the research uses regardless of whether consent was obtained. When we pooled across all vignettes in which each attribute was included and accounted for the multiple vignettes per respondent, participants rated scenarios in which health information was used for research higher than when it was used for marketing (6.27 vs. 4.25; P Ͻ 0.001). They also rated scenarios in which consent was obtained higher than when it was not obtained (5.77 vs. 4.75; P Ͻ 0.001). Participants rated scenarios equally regardless of whether it was described with specific results from a past use or an abstract future use without results (5.30 vs. 5.21; P ϭ 0.46). We tested for independent and joint effects of the 3 health information use attributes using adjusted, interacting generalized estimating equations (Appendix Table 1 , available at www.annals.org). Participants rated scenarios in which consent was obtained as more appropriate than scenarios in which consent was not obtained (1.01 [95% CI, 0.69 to 1.34]; P Ͻ 0.001). Participants rated scenarios in which the use was marketing as less appropriate than when the use was research (Ϫ2.03 [CI, Ϫ2.27 to Ϫ1.78]; P Ͻ 0.001). Participants rated the scenarios with different framing equally (Ϫ0.03 [CI, Ϫ0.37 to 0.30]; P ϭ 0.85 for future abstract benefits vs. past specific benefits).
We also tested for interactions among the information use attributes (consent, use, and framing) and between these attributes and race/ethnicity, and we adjusted for other demographic and health characteristics. Overall, the interactions of use with consent and use with race/ethnicity were significant (Appendix Table 2 , available at www .annals.org). When we described marketing uses to participants, the increase in support from obtaining consent was on average 0.58 points (CI, 0.36 to 0.80 points) smaller than the increase in support with research uses. However, participants rated research uses without consent substantially higher than marketing uses with consent (5.65 vs. 4.52; difference, 1.13 [CI, 0.87 to 1.39]). Non-Hispanic African American and Hispanic respondents rated the marketing scenarios 1.18 (CI, 0.91 to 1.45) and 1.16 (CI, 0.85 to 1.47) points higher, respectively, than white persons. However, respondents from the 3 racial/ethnic groups rated the consent arrangements similarly. The interactions among consent, use, and race/ethnicity are shown in Figure 2 . Because each participant evaluated 2 scenarios describing 2 different uses (research and marketing), we controlled for order effects. Participants rated marketing uses slightly more favorably when preceded by a scenario describing research use (0.28 point higher; P ϭ 0.015); however, they rated research uses similarly regardless of whether it preceded or followed a scenario describing marketing use (P ϭ 0.194). In a separate analysis to further test for order effects, we excluded each participant's response to the second health information use scenario they rated and found similar results.
DISCUSSION
As more health information is available in easily searchable electronic formats, the potential uses of health information will continue to grow. The debate about appropriate stewardship of electronic health information has emphasized developing consent policies that balance patient autonomy with the social benefits of data use. However, researchers and policymakers have not been able to develop a single policy around consent that a majority of the public supports (7) . As a result, there has not been a clear path for managing the use of electronic health information for secondary purposes. Both the Institute of Medicine and the federal government have proposed loosening requirements for consent for information-based research, but regulatory changes have not moved forward. This study reveals 2 key findings that can advance this debate. First, although obtaining consent was an important factor, the purpose of the use of health information was also important. For example, even when consent was obtained, respondents viewed research uses as more appropriate than marketing uses. Second, views about consent policies were consistent across the 3 racial/ethnic groups included in our study, although minority participants rated marketing uses higher than white participants.
When policymakers discuss and debate the privacy of electronic health information and policies concerning secondary uses, they often focus on consent policies. This focus implicitly privileges notions of privacy and autonomy and assumes that consent is the only factor to consider in managing health information. This study suggests that singular focus may be misplaced. Our study shows that patients place as much importance on the purpose toward which their information is used as whether consent is obtained. Thus, we may need to focus more attention on the social value of the information use. Such an approach contrasts with current policies in which research uses of this information are often subjected to the strictest standards of consent (12) , in part because of an established set of rules and processes that surround human subjects participation in academic settings. At a minimum, research is needed to identify better ways to meaningfully obtain consent, particularly for nonresearch uses that currently have less oversight.
Our study has important limitations. First, we asked participants to rate hypothetical scenarios about the use of 
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The interaction of race/ethnicity with different health information uses (research or marketing) and different consent policies (consent obtained or consent not obtained) are shown but holds the framing (a future use) constant. The coefficients represent differences in appropriateness ratings on a scale of 1 (not at all appropriate) to 10 (very appropriate). The reference group is white participants rating a scenario when consent was not obtained and the health information would be used for research. The error bars indicate 95% CIs for the point estimates.
Original Research Consent for Secondary Use of Health Information electronic health information of other patients as opposed to actual uses of their own information. Thus, we do not know how differences in attitudes toward these scenarios would predict differences in personal behavior, such as a willingness to share health information for a particular use versus not sharing. In addition, we tested only 3 attributes, and other important factors probably influence participant attitudes. However, we used an experimental survey design that can more rigorously identify underlying preferences rather than relying on individual participants to express their views across abstract and competing dimensions. Second, we included a statement within the vignettes that "an ethics review board determined that this study provided acceptable safeguards to patient privacy" to standardize the level of privacy oversight. Although this statement could make participants feel that the use of data was more appropriate than they otherwise might have reported, it also reflects the likely reality that an institutional review board would have approved research studies performed in real settings. Third, like all survey research, our findings are vulnerable to nonresponse bias. However, we achieved a relatively high response rate and used poststratification weights to adjust for nonresponse. Furthermore, we randomly assigned participants to alternative scenarios and would have to postulate an unlikely interaction term between nonresponse and the dimensions we studied for nonresponse bias to affect our findings. As more and more health-related information is captured electronically in health, insurance, purchasing records, and a growing variety of digital devices and other media, persons are increasingly leaving electronic footprints with information of enormous value when aggregated across populations. The absence of socially balanced stewardship of this resource potentially squanders its value. The results of this study suggest a need to emphasize not just consent but the purpose of use and the extent to which the public supports that use.
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